Close
Help




JOURNAL

Clinical Medicine Insights: Endocrinology and Diabetes

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?

Submit a Paper


Clinical Medicine Insights: Endocrinology and Diabetes 2012:5 31-37

Consise Review

Published on 11 Apr 2012

DOI: 10.4137/CMED.S9494


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Endocrinology and Diabetes

Abstract

The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a promising future in clinical use. When compared to its rival basal insulin analogs, a longer duration of action and lower incidence of hypoglycemic events in both type 1 and type 2 diabetic patients has been demonstrated.1,2 Its unique mechanism of action is based on multihexamer formation after subcutaneous injection. This reportedly allows for less pharmacodynamic variability and within-subject variability than currently available insulin analogs, and a duration of action that is over 24 hours.3 The lack of proof of carcinogenicity with insulin degludec is yet another factor that would be taken into consideration when choosing the optimal basal insulin for a diabetic individual.4 A formulation of insulin degludec with insulin aspart, Insulin degludec 70%/aspart 30%, may permit improved flexibly of dosing without compromising glycemic control or safety.5



Downloads

PDF  (446.64 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML




What Your Colleagues Say About Clinical Medicine Insights: Endocrinology and Diabetes
I would like to congratulate Clinical Medicine Insights: Endocrinology and Diabetes for the professional way it manages the entire publication process.  I am certain it will have a bright future, and reach top positions among endocrine and metabolic journals.
Dr Francisco Bandeira (University of Pernambuco Medical School, Recife, Brazil)
More Testimonials

Quick Links


New article and journal news notification services